JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms. / Eickhardt-Dalbøge, Christina Schjellerup; Nielsen, Henrik V.; Fuursted, Kurt; Stensvold, Christen Rune; Andersen, Lee O’Brien; Lilje, Berit; Larsen, Morten Kranker; Kjær, Lasse; Christensen, Sarah Friis; Knudsen, Trine Alma; Skov, Vibe; Sørensen, Anders Lindholm; Ellervik, Christina; Olsen, Lars Rønn; Christensen, Jens Jørgen Elmer; Nielsen, Xiaohui Chen; Hasselbalch, Hans Carl; Ingham, Anna Cäcilia.

I: European Journal of Haematology, Bind 112, Nr. 5, 2024, s. 776-787.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Eickhardt-Dalbøge, CS, Nielsen, HV, Fuursted, K, Stensvold, CR, Andersen, LOB, Lilje, B, Larsen, MK, Kjær, L, Christensen, SF, Knudsen, TA, Skov, V, Sørensen, AL, Ellervik, C, Olsen, LR, Christensen, JJE, Nielsen, XC, Hasselbalch, HC & Ingham, AC 2024, 'JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms', European Journal of Haematology, bind 112, nr. 5, s. 776-787. https://doi.org/10.1111/ejh.14169

APA

Eickhardt-Dalbøge, C. S., Nielsen, H. V., Fuursted, K., Stensvold, C. R., Andersen, L. OB., Lilje, B., Larsen, M. K., Kjær, L., Christensen, S. F., Knudsen, T. A., Skov, V., Sørensen, A. L., Ellervik, C., Olsen, L. R., Christensen, J. J. E., Nielsen, X. C., Hasselbalch, H. C., & Ingham, A. C. (2024). JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms. European Journal of Haematology, 112(5), 776-787. https://doi.org/10.1111/ejh.14169

Vancouver

Eickhardt-Dalbøge CS, Nielsen HV, Fuursted K, Stensvold CR, Andersen LOB, Lilje B o.a. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms. European Journal of Haematology. 2024;112(5):776-787. https://doi.org/10.1111/ejh.14169

Author

Eickhardt-Dalbøge, Christina Schjellerup ; Nielsen, Henrik V. ; Fuursted, Kurt ; Stensvold, Christen Rune ; Andersen, Lee O’Brien ; Lilje, Berit ; Larsen, Morten Kranker ; Kjær, Lasse ; Christensen, Sarah Friis ; Knudsen, Trine Alma ; Skov, Vibe ; Sørensen, Anders Lindholm ; Ellervik, Christina ; Olsen, Lars Rønn ; Christensen, Jens Jørgen Elmer ; Nielsen, Xiaohui Chen ; Hasselbalch, Hans Carl ; Ingham, Anna Cäcilia. / JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms. I: European Journal of Haematology. 2024 ; Bind 112, Nr. 5. s. 776-787.

Bibtex

@article{09461f13a8e04933bf66de767b1ae1a3,

title = "JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms",

abstract = "Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.",

keywords = "essential thrombocythemia, gut microbiota, myeloproliferative neoplasms, polycythemia vera, primary myelofibrosis",

author = "Eickhardt-Dalb{\o}ge, {Christina Schjellerup} and Nielsen, {Henrik V.} and Kurt Fuursted and Stensvold, {Christen Rune} and Andersen, {Lee O{\textquoteright}Brien} and Berit Lilje and Larsen, {Morten Kranker} and Lasse Kj{\ae}r and Christensen, {Sarah Friis} and Knudsen, {Trine Alma} and Vibe Skov and S{\o}rensen, {Anders Lindholm} and Christina Ellervik and Olsen, {Lars R{\o}nn} and Christensen, {Jens J{\o}rgen Elmer} and Nielsen, {Xiaohui Chen} and Hasselbalch, {Hans Carl} and Ingham, {Anna C{\"a}cilia}",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.",

year = "2024",

doi = "10.1111/ejh.14169",

language = "English",

volume = "112",

pages = "776--787",

journal = "Scandinavian Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "5",

}

RIS

TY - JOUR

T1 - JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms

AU - Eickhardt-Dalbøge, Christina Schjellerup

AU - Nielsen, Henrik V.

AU - Fuursted, Kurt

AU - Stensvold, Christen Rune

AU - Andersen, Lee O’Brien

AU - Lilje, Berit

AU - Larsen, Morten Kranker

AU - Kjær, Lasse

AU - Christensen, Sarah Friis

AU - Knudsen, Trine Alma

AU - Skov, Vibe

AU - Sørensen, Anders Lindholm

AU - Ellervik, Christina

AU - Olsen, Lars Rønn

AU - Christensen, Jens Jørgen Elmer

AU - Nielsen, Xiaohui Chen

AU - Hasselbalch, Hans Carl

AU - Ingham, Anna Cäcilia

PY - 2024

Y1 - 2024

N2 - Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.

AB - Background: Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis. Methods: We analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next-generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre-MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub-diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub-diagnoses and MPN mutation. Results: MPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p =.003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p <.001). The microbiota of CALR-positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F-positive patients, only minor differences in the gut microbiota were observed between MPN sub-diagnoses, illustrating the importance of this mutation. Conclusion: The gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.

KW - essential thrombocythemia

KW - gut microbiota

KW - myeloproliferative neoplasms

KW - polycythemia vera

KW - primary myelofibrosis

U2 - 10.1111/ejh.14169

DO - 10.1111/ejh.14169

M3 - Journal article

C2 - 38226781

AN - SCOPUS:85182500596

VL - 112

SP - 776

EP - 787

JO - Scandinavian Journal of Haematology

JF - Scandinavian Journal of Haematology

SN - 0902-4441

IS - 5

ER -

ID: 381786924

Institut for Klinisk Medicin